Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
Michael J. Mauro
Current and potential PI3K and BTK inhibitors for CLL
Denosumab: the next big drug in myeloma?
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL